Bulletins - Cannabis-based products
Filter by category:
AdministrationAdverse drug reactionsCannabis-based productsComplementary and Alternative Medicines (CAMs)COVID-19Drug comparisonsInteractionsNew medicineOtherPharmacokineticPregnancy/Breastfeeding


Cannabis-based products (part 1): an overview - May 1, 2020
Since 2018, there have been significant changes to legislation around cannabis-based products in New Zealand with the most recent change in April 2020. This bulletin aims to provide an update on what products are available and the important differences between them.
The cannabis plant (Cannabi...



Cannabis-based products (part 4): Sativex® - May 1, 2020
Sativex® is the only approved cannabis-based product in New Zealand. This bulletin aims to provide information around the safety, efficacy and regulatory status of Sativex®.
What is Sativex®?
Sativex® oral mucosal spray is a pharmaceutical-grade cannabis isolate containing 2.7 mg/spray of t...



Cannabis-based products (part 3): cannabidiol (CBD) - October 14, 2019
The legal status of CBD changed in December 2018 so that it is no longer a controlled drug. CBD is frequently confused with other cannabis-based products. This bulletin aims to clarify the legal status and evidence for CBD.
What is cannabidiol (CBD)?
CBD is one of the two main cannabinoids in c...



Cannabis-based products (part 2): cannabis plant & tetrahydrocannabinol (THC) - October 14, 2019
Legal changes in December 2018 allow the use of the cannabis plant (Cannabis sativa) for palliative care, and prescribed tetrahydrocannabinol (THC) will be more accessible later this year. This bulletin aims to clarify the legal status and evidence for the cannabis plant and its main active const...